Scinovex
article Open AccessTop 1% cited

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

PLoS Pathogens · 2015 · Vol. 11(9) · pp. e1005142–e1005142
Ole S. SøgaardMette E. GraversenSteffen LethRikke OlesenChristel R. BrinkmannSara Konstantin NissenAndreas KjærMariane Høgsbjerg SchleimannPaul W. DentonWilliam J. Hey-CunninghamKersten K. KoelschGiuseppe PantaleoKim KrogsgaardMaja A. SommerfeltRémi FromentinNicolas ChomontThomas A. RasmussenLars ØstergaardMartin Tolstrup

Abstract

clinicaltrials.gov NTC02092116.

HIV Research and TreatmentHIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsRomidepsinDepsipeptideIn vivoHuman immunodeficiency virus (HIV)ChemistryBiologyVirologyGeneticsHistone deacetylaseStereochemistry

MeSH terms

AcetylationAdultDrug InteractionsFemaleFollow-Up StudiesHistonesHumansInfusions, IntravenousLymphocytesMaleMiddle AgedProtein Processing, Post-TranslationalRNA, ViralVirus ActivationCohort Studies

Funding

  • Celgene
  • Norges Forskningsråd
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases
Citations
519
FWCI
29.51
field-weighted impact
References
52
Percentile
100%
vs. same field & year
Citations per year
Cited by
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
British Journal of Clinical Pharmacology · 2021 · 401 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.